Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Reza Moghadam, PharmD, MBA, senior director, Population Health & Remote Customer Engagement with Otsuka Pharmaceuticals on the impact of mental health during COVID-19.
As we continue to wade through another month of societal paralysis due to the COVID-19 pandemic, our country is accelerating quickly toward another potentially more devastating issue that has been ready to boil over for some time: The post-pandemic mental health crisis.
We are already seeing news coverage nationwide highlighting the hardship associated with the emotional and physical strain people are feeling from near-constant fear, social isolation and psychological trauma resulting from this pandemic. Nowhere has the devastating impact on mental health been more apparent than for the health care workers who have been serving on the front-lines treating patients in this pandemic.
While more attention is being given to mental health than ever before, there are still exceptional challenges awaiting us at the end of the pandemic for which it will be critical to prepare. What can this crisis on the front-lines teach us as a broader, collective society? This is an opportunity for all of us – especially health care industry leaders — to pause, learn, and pivot into practices that provide sustainable support for building mental health resiliency.
Data have existed for some time to suggest that even under normal circumstances, emergency room physicians and health care providers face a high level of burnout.1 The COVID-19 crisis has only exacerbated these underlying issues for the majority of our front-line health care workers now serving in an emergency capacity. Add to this the very real anxiety over potentially contracting the virus, along with increased caregiving responsibilities as families and friends are kept away from the ill, and fragile mental threads begin to fray beyond what is typically seen as “classic” burnout.
We are witnessing firsthand the unprecedented toll that this is having on wellbeing, as an uptick in suicides in the New York health care system have unfortunately demonstrated. On a broader scale, a recent Kaiser Family Foundation poll reports that nearly half of Americans report the coronavirus crisis is harming their mental health.2 The key question is how can we, in the pharmaceutical industry, help society prepare for, and provide support and resources that create a safety net to lessen the mental burdens in the event future pandemics occur.
Thus far, we are not moving fast enough. There has been an unequal focus on physical wellbeing as our health care workers endure longer hours, less sleep and de-prioritize their own self-care. When endured for short periods of time — as is typically the case for a normal ER setting — this is mostly manageable. However, for many of us there is no end in sight to how COVID-19 has upended our lives. This has thrown our front-line workers into unprecedented levels of prolonged crisis management. Early trends are showing the broader American workforce is experiencing a similar situation, as we have moved to an almost entirely virtual life.
We’ve picked up the reins to reorient our lives to this new normal, and our collective health and wellness has taken a backseat. Boundaries that barely existed between work and home life are now nonexistent. There is real risk that over time we will see increased levels of post-traumatic stress disorder (PTSD), depression and suicide as a result — similarly to what we’ve seen in the short term among health care workers. We must use the time now to shift from short-term coping mechanisms to long-term support; encouraging a sustained focus on physical and mental wellness, offering access to resources and enabling people to strengthen their mental resiliency.
In the near-term, we must ensure our basic mental health needs are being met. Recent funding measures included only small allocations for mental services, putting even more strain on an already underserved population. An immediate prioritization of awareness and access to behavioral health experts — via hotlines or telemedicine services — is needed. Over time, it will be critical for us to brace for the coming onslaught of mental health illnesses. Offering broader access to screenings and continued scaling of services offered via telemedicine, alongside federal and state financial support will be imperative to prepare us for what lies ahead. There may not be a return to “normal” life before COVID-19, but we must seize the opportunity to recognize this coming crisis so the most vulnerable among us may be offered a better version of mental health care than available today.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Advancing mental health in May and beyond
World Mental Health Day: Supporting access to medicines that help loved ones
The role of antidepressants in addressing America’s mental health crisis
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
Women’s Health Month: A conversation with Sage
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
WHO Pandemic Agreement offers opportunities and risks for American innovators
What you should know about protecting your health this fall
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
Key considerations as Congress works towards PAHPA reauthorization
A conversation with Dr. Mike Ybarra on the current state of COVID-19
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
PhRMA submits comments to OSTP on enhancing clinical trial diversity
What we’ve learned from three years of fighting COVID-19
U.S. must address IP and market access barriers abroad to protect American innovation
New Report More than 160 medicines in development for mental illness
Word of the Month: What is TRIPS?
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
New paper: Addressing the growing crisis of mental health and substance use disorders
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Mental Illness Awareness Week – A time for reflection
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
Spotlighting a growing mental health challenge
A conversation with Barry Greene, CEO of Sage Therapeutics
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
Protecting U.S. innovation abroad to support economic and pandemic recovery
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Navigating the patient experience in the time of COVID-19
Global COVID-19 vaccination matters now and for the future
Understanding breakthrough COVID-19 infections
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
The important role of antivirals in the fight against COVID-19
Understanding Long COVID-19
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
The impact of monoclonal antibodies and COVID-19 recovery
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
PhRMA awards $75,000 to fund initiatives to reduce health inequities
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Americans 12 years of age and older are eligible for COVID-19 vaccines
PhRMA hosts first stakeholder workshop on clinical trial diversity
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
A year later: Reflections on the meaning of equity
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
Reflecting on Mental Health Awareness Month
American leadership on innovation policy is essential to global health progress
Patient safety is at the heart of COVID-19 vaccine R&D
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
Top five issues voters want addressed in the administration’s first 100 days
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Lessons learned from COVID-19: The way we develop new medicines is changing
Action needed to preserve the six protected classes
Growing trend: Increased vaccine confidence
Election insights: Common ground areas to address Americans’ health care concerns
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Election insights: Voter priorities in the states
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Insights from the election: Meeting voters where they are on health care
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Guest Post: Bringing our best to the fight against COVID-19
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Deep dive: The issues that drove the 2020 vote
Understanding the emergency use authorization process for COVID-19 vaccines
Guest Post: Recognizing America’s Veterans
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Voters want to address the real drivers of health care costs for patients and the system
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
The 2020 We Work for Health Champion Awards showcase the best of our industry
Summer reading in the age of COVID-19
The patient perspective navigating COVID-19
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
Executive order threatens R&D when we need it most to fight COVID-19
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
New initiative to bridge the gap on antimicrobial innovation
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
PhRMA awards $100,000 to fund projects that address health inequalities
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
What scientific experts are saying about vaccine safety
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
IP Explained: Intellectual property system working to combat COVID-19
Guest Post: What will we learn from COVID-19?
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
Guest post: Securing the health care supply chain during COVID-19
To the millions affected by COVID-19
New infographic: How we are fighting COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Helping those affected by the coronavirus
Nearly 140 medicines in development to treat mental illness
Opening the conversation around mental health treatment with advocates & industry leaders
Mental health in the New Era of Medicine
Guest post: A post-pandemic crisis: The mental toll on America
Mental Health
Coronavirus
Guest post: A post-pandemic crisis: The mental toll on America
Guest post: A post-pandemic crisis: The mental toll on America